Glycoten-M 500 Tablet ER is a combination oral antidiabetic medication containing Metformin 500 mg and Teneligliptin 20 mg, formulated for extended release to improve glycemic control in patients with type 2 diabetes mellitus. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production, enhancing peripheral glucose uptake, and improving insulin sensitivity, thereby lowering both fasting and postprandial blood glucose levels. Teneligliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, increases incretin hormone levels, which stimulate insulin secretion and suppress glucagon release in a glucose-dependent manner, contributing to improved glycemic regulation. The extended-release formulation of Glycoten-M 500 facilitates once-daily dosing, promoting better patient adherence and minimizing gastrointestinal side effects commonly associated with immediate-release metformin. This combination is indicated as adjunctive therapy to diet and exercise for adult patients inadequately controlled on monotherapy or lifestyle modifications alone. Glycoten-M 500 should be used with caution in patients with renal impairment, hepatic dysfunction, or conditions predisposing to lactic acidosis. Regular monitoring of blood glucose, renal function, and potential adverse effects is recommended to optimize therapeutic outcomes. This product should be prescribed and used under medical supervision to ensure safety and efficacy in managing type 2 diabetes mellitus.